ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded at StockNews.com

StockNews.com upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a sell rating to a hold rating in a report published on Wednesday morning.

Several other equities research analysts have also recently issued reports on the stock. Guggenheim restated a “buy” rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Friday, April 11th. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 price objective for the company. Finally, JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.75.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP opened at $69.21 on Wednesday. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.48. The stock has a 50-day moving average of $63.26 and a 200 day moving average of $59.42. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -125.84 and a beta of 0.49.

Insiders Place Their Bets

In related news, VP Meredith Cook sold 400 shares of the company’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the completion of the transaction, the vice president now owns 80,145 shares of the company’s stock, valued at approximately $5,526,799.20. This represents a 0.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock worth $197,792 over the last quarter. 12.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ANIP. Sowell Financial Services LLC purchased a new position in ANI Pharmaceuticals in the 1st quarter worth approximately $352,000. GAMMA Investing LLC raised its position in shares of ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock valued at $95,000 after buying an additional 881 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of ANI Pharmaceuticals by 41.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company’s stock worth $2,648,000 after buying an additional 13,948 shares in the last quarter. Stonepine Capital Management LLC bought a new position in shares of ANI Pharmaceuticals during the fourth quarter worth $1,128,000. Finally, Rafferty Asset Management LLC purchased a new position in ANI Pharmaceuticals during the fourth quarter valued at $200,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.